Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRTs Combined With SHR-1210 in Advanced Refractory Solid Tumors
NCT03171220Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Neoantigen-reactive T cells, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Number of participants with Adverse Events up to 6 months. Status: unknown.
02
Drugs
Neoantigen-reactive T cells
Beyond the preview
Go deeper on NCT03171220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03171220.